r 18

USP30 inhibitor 18 is a selective USP30 inhibitor with an IC50 of 0.02 μM. USP30 inhibitor 18 increases protein ubiquitination and accelerates mitophagy[1]. [1]. Arthur F Kluge, et al. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg Med Chem Lett. 2018 Aug 15;28(15):2655-2659.

SSR 180 is a potent and subtype-selective α7 agonist with applications in the study of Alzheimer;s disease and schizophrenia.

FR 180204 is a potent and selective ATP-competitive inhibitor of ERK1 and ERK2.

18:1 Hemi BMP (S,R) is a reagent used in biochemical reactions.

Nrf2 activator 18 (Compound 11a) is an orally active activator of the Keap1 Nrf2 HO-1 signaling pathway, promoting Nrf2 nuclear translocation and enhancing antioxidant effects. It inhibits IL-6 release with an IC50 of 4.816 μM. In a mouse model of PM2.5-induced lung injury, Nrf2 activator 18 demonstrates anti-inflammatory activity.

WRN inhibitor 18 (compound 306) is an orally active inhibitor of WRN with demonstrated anticancer activity in vivo.

HIV-1 Inhibitor 18A (HIV-1 Inhibitor-18A) specifically inhibits the entry of multiple HIV-1 isolates.

KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities.

Poloxamer 188 is a nonionic triblock copolymer surfactant and bioactive excipient used as a medical excipient to exacerbate cerebral amyloidosis, presynaptic dystrophy, and pathogenic microglial cell activation in 5XFAD mice.

Tubulin inhibitor 18 (compound 5j) is a highly potent chalcone compound that effectively inhibits tubulin, making it a promising candidate for cancer research [1].

BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.

XR 1853 is a low molecular weight modulator of human plasminogen activator inhibitor-1 activity.

Microtubule inhibitor 185322 is an inhibitor of microtubule assembly, inducung mitotic arrest and apoptosis of MM cells.

Topoisomerase II inhibitor 18 (Compound IV), a Quinoxaline derivative, exhibits an IC 50 of 7.5 μM in inhibiting topoisomerase II. It impedes PC-3 cell proliferation, arrests the cell cycle at the S phase, and induces apoptosis. Moreover, this compound demonstrates substantial antitumor activity against cancer [1].

Poloxamer 188 is a nonionic linear copolymer known for its surfactant properties. In various tissue damage models, Poloxamer 188 demonstrates antithrombotic, anti-inflammatory, and cytoprotective activities.

Poloxamer 184 L64 is a block polymer formed from polyoxyethylene and polyoxypropylene with an average molecular weight of 2900.Poloxamer 184 L64 is toxic to the skin in the short term, as evidenced by mild erythema and intradermal inflammatory reactions. This compound exhibits antimicrobial activity, inhibiting 60% of Mycobacterium avium at a concentration of 1 mg mL.Poloxamer 184 L64 forms thermoreversible hydrogels and is used as a food additive and as a drug delivery vehicle in cosmetics, pharmaceuticals, and tissue engineering.

Sodium phosphate dibasic, formolecular biology is an inorganic salt used in life science research.

Poloxamer 181 L61 is a block copolymer composed of polyoxyethylene and polyoxypropylene, with an average molecular weight of 2000. It exhibits antimicrobial activity and can inhibit 91% of Mycobacterium avium at a concentration of 1 mg mL. Poloxamer 181 L61 can form thermoreversible hydrogels and is used as a food additive and as a drug delivery vehicle in cosmetics, pharmaceuticals, and tissue engineering.

Poloxamer 183 L63 is a block copolymer of polyoxyethylene and polyoxypropylene, with an average molecular weight of 2000. It demonstrates antibacterial activity by inhibiting 83% of Mycobacterium avium at a concentration of 1 mg mL. Poloxamer 183 L63 can form thermoreversible hydrogels and is used as a food additive, as well as a drug delivery carrier in cosmetics, pharmaceuticals, and tissue engineering.

Antagonist of 14.3.3 proteins (KD ≈80 nM). Competitively inhibits 14.3.3-ligand interactions without requiring phosphorylation. Blocks the ability of 14.3.3 to bind to target proteins such as Raf-1, Bad, ASK1 and exoenzyme S.

(S,R)-LSN 3318839 enhances GLP-1R, shows strong blood sugar lowering in animals, works with sitagliptin.

(R)-GNE-140 (GNE-140) is an effective LDHA LDHB inhibitor (IC50s: 3 5 nM) and is 18-fold more potent than S enantiomer.

(S,R,S)-AHPC-p-toluic acid serves as an E3 Ligase Ligand-Linker Conjugate. This compound is utilized in the synthesis of PROTAC SMARCA2 4-degrader-18.

(±)18-HEPE is produced by non-enzymatic oxidation of EPA. It contains equal amounts of 18(S)-HEPE and 18(R)-HEPE. Specific biological activity attributed to (±)18-HEPE has not been documented.